January 13, 2025 07:00 AM ESTUpdated 01:40 PM
Deals
Pharma

#JPM25 live blog: How im­por­tant are this morn­ing’s deals to a biotech re­cov­ery? In­sid­ers weigh in

ENDPOINTS

It’s day 1 at JP Mor­gan Health­care Con­fer­ence, and the deal­mak­ing is al­ready un­der­way with three ear­ly an­nounce­ments: GSK will ac­quire the pri­vate­ly-held biotech IDRx …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

J&J to buy In­tra-Cel­lu­lar for $14.6B in lat­est neu­ro­science bet

Lil­ly to ac­quire can­cer biotech Scor­pi­on, which shares a co-founder with Loxo

GSK kicks off JPM deal­mak­ing with $1B+ buy­out of IDRx and its rare can­cer drug

Gilead taps in­to STAT6 space via $250M deal with Leo Phar­ma

Hen­grui and Kail­era’s in­ject­ed in­cretin posts best-in-class obe­si­ty da­ta in Phase 2 tri­al

Bio­gen of­fers to buy out strug­gling neu­ro part­ner Sage Ther­a­peu­tics

A service from the Financial Times